1. Denmark Stocks

  2. •

    Basic Materials

  3. •

    Chemicals - Specialty
Novozymes A/S

Novozymes A/S

NSIS-B.CO
Novozymes A/SDK flagNASDAQ Copenhagen
425.00
DKK
+2.60
- -
198.15BMarket Cap
Novozymes A/S
NSIS-B.CO
(NASDAQ Copenhagen)

Recent

price

425.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
4.16
4.49
4.8
5.02
5.36
6.13
6.33
6.61
6.64
6.75
6.71
7.23
8.52
8.67
8.38
8.92
6.71
Revenue per Share
0.69
0.78
0.86
0.94
1.09
1.24
1.37
1.42
1.49
1.48
1.35
1.52
1.78
1.47
0.67
1.25
0.98
Basic EPS, GAAP
0.43
0.61
0.7
0.78
1.65
1.04
1.24
1.12
1.08
1.1
1.71
1.45
0.6
1.02
1.49
1.74
0.88
Free Cash Flow per Basic Share
0.15
0.22
0.26
0.3
0.34
0.4
0.48
0.54
0.61
0.68
0.71
0.71
0.74
1.38
0.55
0.86
1.13
Dividend per Share
3.75
3.57
3.89
4.65
4.67
4.83
4.97
5.22
5.32
5.35
5.67
5.74
6.61
6.93
24.38
24.22
24
Book Value per Share
2.9
2.82
2.94
3.5
3.58
3.9
4.03
4.02
4.29
4.48
4.16
3.47
4.62
4.76
2.52
-0.5
-0.47
Tangible Book Value per Share
313
315
314
314
312
306
300
295
290
285
280
278
277
277
458
466
467
Basic Weighted Avg Shares
1,304
1,415
1,506
1,574
1,673
1,876
1,903
1,952
1,927
1,924
1,883
2,010
2,356
2,402
3,834
4,158
3,134
Sales/Revenue/Turnover
21.77
22.08
24.43
24.7
25.26
27.74
27.9
28.31
28.28
24.66
25.76
25.98
25.23
25.43
17.19
21.23
21.73
Operating Margin (%)
- -
102
94
99
116
128
131
140
146
158
170
185
196
186
544
575
- -
Depreciation Expense
216
246
270
295
339
378
410
419
432
422
380
423
493
406
306
584
459
Net Income, GAAP
23.98
24.31
21.98
20.22
22.99
21.98
21.41
19.5
18.01
16.95
19.74
19.85
19.1
22.26
26.68
21.5
21.47
Effective Tax Rate (%)
16.6
17.37
17.94
18.73
20.27
20.16
21.57
21.46
22.42
21.94
20.16
21.04
20.94
16.9
7.98
14.04
14.63
Profit Margin (%)
406
327
265
433
452
382
381
210
175
310
370
289
306
297
791
-758
823
Working Capital
- -
204
228
227
162
161
231
175
197
432
488
543
524
612
1,530
- -
2,923
LT Debt
1,051
1,188
1,282
1,483
1,515
1,553
1,580
1,513
1,532
1,536
1,511
1,641
1,910
1,926
11,176
10,855
10,920
Total Equity
23.2
19.25
19.34
18.67
18.4
22.97
23.13
23.97
23.05
19.46
19.15
18.37
17.9
16.31
6.05
5.78
7.51
Return on Invested Capital (%)
21.07
20.2
19.59
18.95
20.31
22.77
24.42
23.52
22.62
21.78
18.95
18.97
19.06
14.52
4.53
5.26
6.36
Return on Capital (%)
20.08
21.39
23.02
21.99
23.27
25.79
27.63
27.61
28
27.5
24.38
26.56
28.82
21.65
4.68
5.2
8.18
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
303
- -
289
LT Borrowings
2,805
- -
2,923
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
466
466
466
Market Capitalization
180,690
190,998
178,770

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,983
2,046
Cash, Cash Equivalents & STI
- -
296
329
Accounts Receivable, Net
- -
716
756
Inventories
- -
772
793
Total Current Liabilities
- -
2,741
1,222
Payables & Accruals
- -
- -
- -
ST Debt
303
- -
289
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
50.07%
100.67%
-2.87%
Free Cash Flow
20.88%
31.04%
19.09%
Net Income, GAAP
7.79%
15.3%
90.84%
Sales/Revenue/Turnover
9.44%
18.79%
8.45%
Total Cash Common Dividend
16.66%
23.27%
61.21%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
854
978
981
- -
3,834
2025
1,078
1,018
- -
997
4,158
2026
1,119
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.08
0.06
0.19
- -
0.67
2025
0.4
0.29
- -
- -
1.25
2026
0.43
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.24
- -
- -
0.55
2025
- -
0.56
- -
- -
0.86
2026
0.57
- -
- -
- -
- -
Similar Companies
Chr. Hansen Holding A/S (CHYHY)
Sakai Chemical Industry Co., Ltd. (4078.T)
Kaneka Corporation (KANKF)
SP Samhwa Co., Ltd. (000390.KS)
SRF Limited (SRF.BO)
Asia Cuanon Technology (Shanghai) Co.,Ltd. (603378.SS)
Business
Novonesis A/S (formerly Novozymes A/S) develops and produces industrial enzymes, microorganisms, biopharmaceutical ingredients, and biosolutions for multiple sectors including agriculture, bioenergy, biopharma, food and beverage, household care, leather, pulp and paper, textile, and wastewater treatment; core offerings encompass lipases, proteases, oxidoreductases, carbohydrases, and specialized enzymes for dairy, baking, beverages, meat, plant-based foods, and functional nutrition, alongside probiotics, biopolymers, and proteins serving over 40 industries globally. Founded in 2000 as a spin-off from Novo Nordisk with roots tracing to 1925, the company is headquartered in Bagsværd, Denmark, and maintains production and R&D facilities across more than 140 countries, including the United States, China, Brazil, India, and the United Kingdom. In January 2024, Novozymes merged with Chr. Hansen in a statutory combination approved by regulators to form Novonesis, creating a global biosolutions leader with projected 6-8% organic sales growth through 2025, EUR 200 million in revenue synergies, and enhanced capabilities in biological innovation for sustainable applications.